BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
India currently hosts more than 10,075 biotech startups
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
The platform is being introduced to expand access to treatments for people living with chronic conditions
Subscribe To Our Newsletter & Stay Updated